摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-methyl-1H-indazole-5-thiol | 1072433-60-3

中文名称
——
中文别名
——
英文名称
1-methyl-1H-indazole-5-thiol
英文别名
1-methylindazole-5-thiol
1-methyl-1H-indazole-5-thiol化学式
CAS
1072433-60-3
化学式
C8H8N2S
mdl
——
分子量
164.231
InChiKey
XWBFBVNWYSDXRA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    18.8
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS<br/>[FR] COMPOSÉS COMPRENANT UN NOYAU À TROIS CYCLES EN TANT QUE BLOQUEURS DE PD-1/PD-L1
    申请人:RELIVE THERAPEUTICS INC
    公开号:WO2021248231A1
    公开(公告)日:2021-12-16
    The present disclosure relates to compounds of Formula (I): (I), wherein R1, R2, L1, L2, Y1, Y2, Y3, X1, Ring A, Ring B and Ring C are as defined herein, as well as to compositions comprising such compounds. The compounds and compositions may be useful for treating diseases and conditions that are amenable to treatment by blocking PD-1, PD-L1 and/or the PD-1/PD-L1 interaction, cancers, sepsis and/or autoimmune diseases.
    本公开涉及式(I)的化合物:(I),其中R1、R2、L1、L2、Y1、Y2、Y3、X1、环A、环B和环C的定义如本文所述,以及包含这些化合物的组合物。这些化合物和组合物可能用于治疗可通过阻断PD-1、PD-L1和/或PD-1/PD-L1相互作用而治疗的疾病和病况,如癌症、败血症和/或自身免疫疾病。
  • Novel 2-pyridinecarboxamide derivatives
    申请人:Mitsuya Morihiro
    公开号:US20060258701A1
    公开(公告)日:2006-11-16
    The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.
    本发明涉及一种化合物,具有激活葡萄糖激酶的效果,并可用作糖尿病治疗剂,其化学式表示为(I):[其中X1表示氮原子、硫原子、氧原子或类似物;R1表示6-至10-成员芳基基团、5-至7-成员杂芳基基团或类似物;D表示氧原子或硫原子;R和R3相同或不同,分别表示氢原子、低碳基或类似物;式(II)表示可选取代的5-至7-成员杂芳基团或类似物;式(III)表示单环或双环杂芳基团]或其药学上可接受的盐。
  • 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
    申请人:Schumacher Richard A.
    公开号:US20100056491A1
    公开(公告)日:2010-03-04
    The present disclosure provides compounds having affinity for the 5-HT 6 receptor which are of the formula (I): wherein Cy is selected from and wherein R 1 , R 2 , R 3 , Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本公开提供了具有对5-HT6受体亲和力的化合物,其化学式为(I):其中Cy选自和,其中R1、R2、R3、Q、G、Ar、m、n和p的定义如本文所述。本公开还涉及制备这种化合物的方法、含有这种化合物的组合物以及使用这种化合物的方法。
  • AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS
    申请人:Studley John
    公开号:US20120095014A1
    公开(公告)日:2012-04-19
    The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    本发明涉及用作Aurora蛋白激酶抑制剂的化合物。该发明还提供了包含这些化合物的药学上可接受的组合物以及使用这些化合物和组合物治疗各种疾病、病况和障碍的方法。该发明还提供了制备本发明化合物的方法。
  • NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES
    申请人:MSD K.K.
    公开号:EP1598349B1
    公开(公告)日:2011-07-27
查看更多